Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2576-2597

  Dorlo, Thomas P C ^a,b   Balasegaram, Manica ^c   Beijnen, Jos H ^b   de vries, Peter J ^a,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c Drugs for Neglected Diseases initiative DNDi   (Switzerland)

^d Division of Internal Medicine   (Netherlands)

Author keywords

Alkylphosphocholine; Antiparasitic agents; Antiprotozoal agents; Clinical pharmacology; Cutaneous leishmaniasis; Leishmania; Mechanism of action; Pharmacodynamics; Pharmacokinetics; Pre clinical pharmacology; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE; MILTEFORAN; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

AFRICA; ANOREXIA; ANTHELMINTIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTHRALGIA; ASIA; CHILL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG ABSORPTION; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; ENDEMIC DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA TROPICA; LEISHMANIASIS; LIPID METABOLISM; LIVER TOXICITY; MALE FERTILITY; MIXED INFECTION; MONOTHERAPY; MOTION SICKNESS; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; RECOMMENDED DRUG DOSE; REPRODUCTIVE TOXICITY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN LEISHMANIASIS; STEADY STATE; SYSTEMATIC REVIEW; TERATOGENICITY; TESTIS ATROPHY; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; VISCERAL LEISHMANIASIS;

ANTIPROTOZOAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEISHMANIA; LEISHMANIASIS; PHOSPHORYLCHOLINE; TREATMENT OUTCOME;

EID: 84867610036     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks275     Document Type: Review

References (191)

1. Murray HW, Berman JD, Davies CR et al. Advances in leishmaniasis. Lancet 2005; 366: 1561-77.
2. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Micro 2007; 5: 873-82.
3. Sengupta PC. History of kala-azar in India. Indian Med Gaz 1947; 82: 281-6.
4. Croft SL. Monitoring drug resistance in leishmaniasis. Trop Med Int Health 2001; 6: 899-905.
5. Hailu A, Musa A, Wasunna M et al. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis 2010; 4: e709.
6. Croft SL. Kinetoplastida: new therapeutic strategies. Parasite 2008; 15: 522-7.
7. Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31: 1104-7.
8. Thakur CP, Narayan S, Ranjan A. Epidemiological, clinical and pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 2004; 120: 166-72.
9. Bern C, Adler-Moore J, Berenguer J et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006; 43: 917-24.
10. Edwards T, Omollo R, Khalil EAG et al. Single-dose liposomal amphotericin B (AmBisomew) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials 2011; 12: 66.
11. Sundar S, Chakravarty J, Agarwal D et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362: 504-12.
12. Soto J, Fuya P, Herrera R et al. Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 1998; 26: 56-8.
13. Jha TK, Olliaro P, Thakur CPN et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998; 316: 1200-5.
14. Musa AM, Younis B, Fadlalla A et al. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis 2010; 4: e855.
15. el-On J, Livshin R, Paz ZE et al. Topical treatment of cutaneous leishmaniasis. Br Med J (Clin Res Ed) 1985; 291: 1280-1.
16. Chunge CN, Owate J, Pamba HO et al. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990; 84: 221-5.
17. Thakur CP, Olliaro P, Gothoskar S et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992; 86: 615-6.
18. Teklemariam S, Hiwot AG, Frommel D et al. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 1994; 88: 334-9.
19. Seaman J, Pryce D, Sondorp HE et al. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993; 168: 715-20.
20. Sundar S, Sinha PK, Rai M et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011; 377: 477-86.
21. Dorlo TPC, Kager PA. Pentamidine dosage: a base/salt confusion. PLoS Negl Trop Dis 2008; 2: e225.
22. ClinicalTrials.gov. Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients with Pentamidine: A Cohort Study (NCT01360762). 2011. http://clinicaltrials.gov/ct2/show/NCT01360762 (16 December 2011, date last accessed).
23. Patel TA, Lockwood DN. Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases. Trop Med Int Health 2009; 14: 1064-70.
24. Croft SL, Engel J. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1: S4-8.
25. Smorenburg CH, Seynaeve C, Bontenbal M et al. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anticancer Drugs 2000; 11: 825-8.
26. Verweij J, Planting A, van der Burg M et al. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol 1992; 118: 606-8.
27. Verweij J, Gandia D, Planting AS et al. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. Eur J Cancer 1993; 29A: 778-9.
28. Planting AS, Stoter G, Verweij J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer 1993; 29A: 518-9.
29. Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100: S17-20.
30. Kuhlencord A, Maniera T, Eibl H et al. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36: 1630-4.
31. Sundar S, Rosenkaimer F, Makharia MK et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998; 352: 1821-3.
32. Engel J. Miltefosine, the story of a successful partnership: disease endemic country-TDR-pharmaceutical industry (Zentaris). TDR News 2002; 68: 5.
33. Paladin Labs Inc. Application for Inclusion of Miltefosine on WHO Model List of Essential Medicines. 2010. http://www.who.int/selection_medicines/committees/expert/18/applications/Miltefosine_application.pdf (13 December 2011, date last accessed).
34. Ruiter GA, Zerp SF, Bartelink H et al. Anti-cancer alkyllysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003; 14: 167-73.
35. Croft SL, Seifert K, Duchêne M. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 2003; 126: 165-72.
36. Brachwitz H, Vollgraf C. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol Ther 1995; 66: 39-82.
37. Achterberg V, Gercken G. Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes. Mol Biochem Parasitol 1987; 23: 117-22.
38. Leder GH, Fiebig HH, Wallbrecher E et al. In vitro and in vivo cytotoxicity of alkyl lysophospholipid ET-18-OCH3 and thioether lipid BM 41.440. Lipids 1987; 22: 958-61.
39. Hilgard P, Klenner T, Stekar J et al. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 1997; 33: 442-6.
40. German Drug Registration Authorities. Impavido 10/50 mg Kapseln- Fachinformation. 2008. http://www.pharmnet-bund.de/dynamic/de/index.html (15 February 2010, date last accessed).
41. Central Drugs Standard Control Organization, Directorate General of Health Services-Government of India. List of Finished Formulation Registered from 2003 to 2009. 2009. http://cdsco.nic.in/html/finished_formulation_drug_registered.htm (14 December 2011, date last accessed).
42. Dorlo TPC, Eggelte TA, de Vries PJ et al. Characterization and identification of suspected counterfeit miltefosine capsules. Analyst 2012; 137: 1265-74.
43. Dorlo TPC, Eggelte TA, Schoone GJ et al. A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal. PLoS Negl Trop Dis 2012; 6: e1544.
44. WHO. WHO Model List of Essential Medicines-17th List. 2011. http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf (13 December 2011, date last accessed).
45. Murray HW. Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg 2012; 86: 434-40.
46. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 2005; 83: 394-5.
47. Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 2007; 3: 733-40.
48. Dorlo TPC, Huitema ADR, Beijnen JH et al. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob Agents Chemother 2012; 56: 3864-72.
49. Harhay MO, Olliaro PL, Vaillant M et al. Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia. Am J Trop Med Hyg 2011; 84: 543-50.
50. Vanlerberghe V, Diap G, Guerin PJ et al. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. Trop Med Int Health 2007; 12: 274-83.
51. Olliaro P, Darley S, Laxminarayan R et al. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009; 14: 918-25.
52. Meheus F, Balasegaram M, Olliaro P et al. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis 2010; 4: e818.
53. Dorlo TPC, Hillebrand MJX, Rosing H et al. Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 865: 55-62.
54. Dorlo TPC, van Thiel PPAM, Huitema ADR et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008; 52: 2855-60.
55. Woo EW, Messmann R, Sausville EA et al. Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Appl 2001; 759: 247-57.
56. Knebel NG, Grieb S, Winkler M et al. Quantification of perifosine, an alkylphosphocholine anti-tumour agent, in plasma by pneumatically assisted electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J Chromatogr B Biomed Appl 1999; 721: 257-69.
57. Blanco-Príeto MJ, Campanero MA, Mollinedo F. Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography-electrospray mass spectrometry: application to cell uptake studies and characterization of drug delivery systems. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 810: 85-92.
58. Lindner LH, Eibl H, Hossann M et al. Quantification of erufosine, the first intravenously applicable alkylphosphocholine, in human plasma by isotope dilution liquid chromatography-tandem mass spectrometry using a deuterated internal standard. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 869: 16-9.
59. Jiang H, Cannon MJ, Banach M et al. Quantification of CLR1401, a novel alkylphosphocholine anticancer agent, in rat plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1513-8.
60. Omollo R, Alexander N, Edwards T et al. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials 2011; 12: 166.
61. ClinicalTrials.gov. Pharmacokinetics of Miltefosine in Children and Adults (NCT01462500). 2011. http://clinicaltrials.gov/ct2/show/record/NCT01462500 (20 January 2012, date last accessed).
62. Kötting J, Marschner NW, Neumüller W et al. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. Prog Exp Tumor Res 1992; 34: 131-42.
63. Ménez C, Buyse M, Dugave C et al. Intestinal absorption of miltefosine: contribution of passive paracellular transport. Pharm Res 2007; 24: 546-54.
64. Ménez C, Buyse M, Farinotti R et al. Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process. Lipids 2007; 42: 229-40.
65. Ménez C, Buyse M, Chacun H et al. Modulation of intestinal barrier properties by miltefosine. Biochem Pharmacol 2006; 71: 486-96.
66. Breiser A, Kim D, Fleer E et al. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids 1987; 22: 925-6.
67. Marschner N, Kötting J, Eibl H et al. Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Cancer Chemother Pharmacol 1992; 31: 18-22.
68. Müller G, Petry S. Lipases and Phospholipases in Drug Development: From Biochemistry to Molecular Pharmacology. Weinheim: Wiley-VCH, 2004.
69. Bianciardi P, Brovida C, Valente M et al. Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys. Toxicol Pathol 2009; 37: 770-5.
70. Dorlo TPC, van Thiel PPAM, Schoone GJ et al. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoS Negl Trop Dis 2011; 5: e1436.
71. de Vallière S, Mary C, Joneberg JE et al. AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg 2009; 81: 209-12.
72. de Vries PJ, van der Meide WF, Godfried MH et al. Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA. Trans R Soc Trop Med Hyg 2006; 100: 1183-6.
73. Dorlo T. Erratum: AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg 2009; 81: 732.
74. van Thiel PPAM, Leenstra T, Kager PA et al. Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 2010; 50: 80-3.
75. Bhattacharya SK, Jha TK, Sundar S et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004; 38: 217-21.
76. Jha TK, Sundar S, Thakur CP et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795-800.
77. Dorlo TPC, Balasegaram M, Lima MA et al. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. J Antimicrob Chemother 2012; 67: 1996-2004.
78. Croft SL, Neal RA, Pendergast W et al. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987; 36: 2633-6.
79. Vermeersch M, da Luz RI, Toté K et al. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 2009; 53: 3855-9.
80. da Luz RI, Vermeersch M, Dujardin J-C et al. In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob Agents Chemother 2009; 53: 5197-203.
81. Seifert K, Escobar P, Croft SL. In vitro activity of antileishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 2010; 65: 508-11.
82. Yardley V, Croft SL, De Doncker S et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 2005; 73: 272-5.
83. Escobar P, Matu S, Marques C et al. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop 2002; 81: 151-7.
84. Lux H, Hart DT, Parker PJ et al. Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Adv Exp Med Biol 1996; 416: 201-11.
85. Zufferey R, Allen S, Barron T et al. Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major. J Biol Chem 2003; 278: 44708-18.
86. Lux H, Heise N, Klenner T et al. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol Biochem Parasitol 2000; 111: 1-14.
87. Rakotomanga M, Saint-Pierre-Chazalet M, Loiseau PM. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob Agents Chemother 2005; 49: 2677-86.
88. Rakotomanga M, Blanc S, Gaudin K et al. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007; 51: 1425-30.
89. Zufferey R, Mamoun CB. Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. Mol Biochem Parasitol 2002; 125: 127-34.
90. Das M, Mukherjee SB, Shaha C. Hydrogen peroxide induces apoptosis-like death in Leishmania donovani promastigotes. J Cell Sci 2001; 114: 2461-9.
91. Paris C, Loiseau PM, Bories C et al. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004; 48: 852-9.
92. Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 2004; 48: 3010-5.
93. Marinho F de A, Gonçalves KC da S, de Oliveira SS et al. Miltefosine induces programmed cell death in Leishmania amazonensis promastigotes. Mem Inst Oswaldo Cruz 2011; 106: 507-9.
94. Khademvatan S, Gharavi MJ, Saki J. Miltefosine induces metacaspase and PARP genes expression in Leishmania infantum. Braz J Infect Dis 2011; 15: 442-8.
95. Moreira W, Leprohon P, Ouellette M. Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death Dis 2011; 2: e201.
96. Santa-Rita RM, Henriques-Pons A, Barbosa HS et al. Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J Antimicrob Chemother 2004; 54: 704-10.
97. Luque-Ortega JR, Rivas L. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007; 51: 1327-32.
98. Zuo X, Djordjevic JT, Bijosono Oei J et al. Miltefosine induces apoptosis-like cell death in yeast via Cox9p in cytochrome c oxidase. Mol Pharmacol 2011; 80: 476-85.
99. Zeisig R, Rudolf M, Eue I et al. Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J Cancer Res Clin Oncol 1995; 121: 69-75.
100. Wadhone P, Maiti M, Agarwal R et al. Miltefosine promotes IFN-g-dominated anti-leishmanial immune response. J Immunol 2009; 182: 7146-54.
101. Escobar P, Yardley V, Croft SL. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 2001; 45: 1872-5.
102. Hochhuth CH, Vehmeyer K, Eibl H et al. Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol 1992; 141: 161-8.
103. Eue I. Hexadecylphosphocholine selectively upregulates expression of intracellular adhesion molecule-1 and class I major histocompatibility complex antigen in human monocytes. J Exp Ther Oncol 2002; 2: 333-6.
104. Griewank K, Gazeau C, Eichhorn A et al. Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions. Antimicrob Agents Chemother 2010; 54: 652-9.
105. Weller K, Artuc M, Jennings G et al. Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo. J Invest Dermatol 2008; 129: 496-8.
106. Hartmann K, Siebenhaar F, Belloni B et al. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebocontrolled trial. Br J Dermatol 2010; 162: 185-90.
107. Cummings HE, Barbi J, Reville P et al. Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis. Proc Natl Acad Sci USA 2012; 109: 1251-6.
108. Liu D, Zhang T, Marshall AJ et al. The p110d isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. J Immunol 2009; 183: 1921-33.
109. van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des 2008; 14: 2061-74.
110. Berkovic D, Sievers S, Haase D et al. Effects of hexadecylphosphocholine on phosphatidylcholine and phosphatidylserine metabolism in human lymphoma cells. J Exp Ther Oncol 2002; 2: 85-92.
111. van der Luit AH, Budde M, Ruurs P et al. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem 2002; 277: 39541-7.
112. Carrasco MP, Jiménez-López JM, Segovia JL et al. Hexadecylphosphocholine interferes with the intracellular transport of cholesterol in HepG2 cells. FEBS J 2008; 275: 1675-86.
113. Chakrabandhu K, Huault S, Hueber A-O. Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine). FEBS Lett 2008; 582: 4176-84.
114. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996; 38: 1041-7.
115. Konstantinov SM, Kaminsky R, Brun R et al. Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies. Acta Trop 1997; 64: 145-54.
116. Saraiva VB, Gibaldi D, Previato JO et al. Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother 2002; 46: 3472-7.
117. Lira R. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother 2001; 47: 537-46.
118. Santa-Rita RM, Santos Barbosa H, Meirelles MN et al. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop 2000; 75: 219-28.
119. Malaquias AT, Oliveira MM. Phospholipid signalling pathways in Trypanosoma cruzi growth control. Acta Tropica 1999; 73: 93-108.
120. Seifert K, Duchêne M, Wernsdorfer WH et al. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob Agents Chemother 2001; 45: 1505-10.
121. Walochnik J, Duchêne M, Seifert K et al. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob Agents Chemother 2002; 46: 695-701.
122. Polat ZA, Obwaller A, Vural A et al. Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. Parasitol Res 2012; 110: 515-20.
123. Blaha C, Duchêne M, Aspöck H et al. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis. J Antimicrob Chemother 2006; 57: 273-8.
124. Shahiduzzaman M, Dyachenko V, Obwaller A et al. Combination of cell culture and quantitative PCR for screening of drugs against Cryptosporidium parvum. Vet Parasitol 2009; 162: 271-7.
125. Sinkala E, Katubulushi M, Sianongo S et al. In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality. Ann Trop Med Parasitol 2011; 105: 129-34.
126. Eissa MM, El-Azzouni MZ, Amer EI et al. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int J Parasitol 2011; 41: 235-42.
127. Bertão HG, da Silva RAR, Padilha RJR et al. Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms. Parasitol Res 2012; 110: 2465-73.
128. Llull D, Rivas L, García E. In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci. Antimicrob Agents Chemother 2007; 51: 1844-8.
129. Obando D, Widmer F, Wright LC et al. Synthesis, antifungal and antimicrobial activity of alkylphospholipids. Bioorg Med Chem 2007; 15: 5158-65.
130. Huelves L, Del Prado G, Gracia M et al. In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains. J Chemother 2008; 20: 441-4.
131. Walochnik J, Obwaller A, Gruber F et al. Anti-Acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent. J Antimicrob Chemother 2009; 64: 539-45.
132. Widmer F, Wright LC, Obando D et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother 2006; 50: 414-21.
133. Tong Z, Widmer F, Sorrell TC et al. In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes. Antimicrob Agents Chemother 2007; 51: 2219-22.
134. Chugh P, Bradel-Tretheway B, Monteiro-Filho CMR et al. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology 2008; 5: 11.
135. Lucas A, Kim Y, Rivera-Pabon O et al. Targeting the PI3K/Akt cell survival pathway to induce cell death of HIV-1 infected macrophages with alkylphospholipid compounds. PLoS ONE 2010; 5: e13121.
136. Seifert K, Matu S, Javier Pé rez-Victoria F et al. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 2003; 22: 380-7.
137. Pérez-Victoria FJ, Castanys S, Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother 2003; 47: 2397-403.
138. Pérez-Victoria FJ, Gamarro F, Ouellette M et al. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 2003; 278: 49965-71.
139. Pérez-Victoria FJ, Sánchez-Cañete MP, Castanys S et al. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J Biol Chem 2006; 281: 23766-75.
140. Sánchez-Cañete MP, Carvalho L, Pé rez-Victoria FJ et al. Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob Agents Chemother 2009; 53: 1305-13.
141. Weingärtner A, Drobot B, Herrmann A et al. Disruption of the lipid-transporting LdMT-LdRos3 complex in Leishmania donovani affects membrane lipid asymmetry but not host cell invasion. PLoS ONE 2010; 5: e12443.
142. Seifert K, Pérez-Victoria FJ, Stettler M et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents 2007; 30: 229-35.
143. Pérez-Victoria JM, Pérez-Victoria FJ, Parodi-Talice A et al. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob Agents Chemother 2001; 45: 2468-74.
144. Pérez-Victoria JM, Cortés-Selva F, Parodi-Talice A et al. Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to miltefosine by inhibiting drug efflux. Antimicrob Agents Chemother 2006; 50: 3102-10.
145. Castanys-Muñoz E, Alder-Baerens N, Pomorski T et al. A novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids. Mol Microbiol 2007; 64: 1141-53.
146. Castanys-Muñoz E, Pérez-Victoria JM, Gamarro F et al. Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement. Antimicrob Agents Chemother 2008; 52: 3573-9.
147. Coelho AC, Boisvert S, Mukherjee A et al. Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing. PLoS Negl Trop Dis 2012; 6: e1512.
148. Zerpa O, Ulrich M, Blanco B et al. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 2007; 156: 1328-35.
149. Pandey BD, Pandey K, Kaneko O et al. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am J Trop Med Hyg 2009; 80: 580-2.
150. Calvopina M, Gomez EA, Sindermann H et al. Relapse of New World diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg 2006; 75: 1074-7.
151. Sundar S, Singh A, Rai M et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis after a decade of use in India. Clin Infect Dis 2012; doi:10.1093/cid/cis474.
152. Cojean S, Houzé S, Haouchine D et al. Leishmania resistance to miltefosine associated with genetic marker. Emerging Infect Dis 2012; 18: 704-6.
153. Bhattacharya SK, Sinha PK, Sundar S et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007; 196: 591-8.
154. Soto J, Soto P. Miltefosine: oral treatment of leishmaniasis. Expert Rev Anti Infect Ther 2006; 4: 177-85.
155. Rybczynska M, Liu R, Lu P et al. MDR1 causes resistance to the antitumour drug miltefosine. Br J Cancer 2001; 84: 1405-11.
156. Má rián T, Balkay L, Trón L et al. Effects of miltefosine on membrane permeability and accumulation of [99mTc]-hexakis-2-methoxyisobutyl isonitrile, 2-[18F]fluoro-2-deoxy-D-glucose, daunorubucin and rhodamine123 in multidrug-resistant and sensitive cells. Eur J Pharm Sci 2005; 24: 495-501.
157. Ritmeijer K, Dejenie A, Assefa Y et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006; 43: 357-64.
158. Rahman M, Ahmed B-N, Faiz MA et al. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg 2011; 85: 66-9.
159. ClinicalTrials.gov. Miltefosine for Brazilian Visceral Leishmaniasis (NCT00378495). 2011. http://clinicaltrials.gov/ct2/show/NCT00378495 (14 February 2012, date last accessed).
160. ClinicalTrials.gov. Phase III, Study of Three Short Course Combination Regimens (AmBisomew, Miltefosine, Paromomycin) Compared with AmBisomew Alone for the Treatment of Visceral Leishmaniasis in Bangladesh (NCT01122771). 2011. http://clinicaltrials.gov/ct2/show/NCT01122771 (19 January 2012, date last accessed).
161. Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 2006; 50: 73-9.
162. van Griensven J, Balasegaram M, Meheus F et al. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010; 10: 184-94.
163. Sindermann H, Engel KR, Fischer C et al. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in patients with HIV infection. Clin Infect Dis 2004; 39: 1520-3.
164. Soto J, Rea J, Balderrama M et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78: 210-1.
165. Gonzá lez U, Pinart M, Reveiz L et al. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 2010; 51: 409-19.
166. Khandpur S, Chaturvedi P, Kumar U et al. Oral miltefosine in post-kala-azar dermal leishmaniasis-experience in three cases. Int J Dermatol 2010; 49: 565-9.
167. Sundar S, Kumar K, Chakravarty J et al. Cure of antimonyunresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg 2006; 100: 698-700.
168. Belay AD, Asafa Y, Mesure J et al. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy. Ann Trop Med Parasitol 2006; 100: 223-7.
169. Ramesh V, Ansari NA, Jain RK et al. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis. Clin Exp Dermatol 2008; 33: 103-5.
170. Ramesh V, Katara GK, Verma S et al. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. Br J Dermatol 2011; 165: 411-4.
171. Schmidt-Ott R, Klenner T, Overath P et al. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1999; 93: 85-90.
172. Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002; 3: 538-44.
173. Sundar S, Mondal D, Rijal S et al. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal-the challenges for diagnosis and treatment. Trop Med Int Health 2008; 13: 2-5.
174. Government of India-National Vector Borne Disease Control Programme. Guideline on Use of Miltefosine. http://nvbdcp.gov.in/Doc/Guidelines%20on%20miltefosine.pdf (12 December 2011, date last accessed).
175. Kaladrug-R. Project: New Tools for Monitoring Drug Resistance and Treatment Response in Visceral Leishmaniasis in the Indian Subcontinent. http://ec.europa.eu/research/health/infectious-diseases/neglected-diseases/projects/002_en.html (9 March 2012, date last accessed).
176. WHO. WHO Technical Report Series 949: Control of the Leishmaniases. Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf (14 February 2012, date last accessed).
177. Sundar S, Gupta LB, Makharia MK et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999; 93: 589-97.
178. Sundar S, Makharia A, More DK et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000; 31: 1110-3.
179. Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739-46.
180. Sundar S, Jha TK, Sindermann H et al. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003; 22: 434-8.
181. Singh UK, Prasad R, Mishra OP et al. Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study. Indian J Pediatr 2006; 73: 1077-80.
182. Sundar S, Rai M, Chakravarty J et al. Newtreatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008; 47: 1000-6.
183. Soto J, Toledo J, Gutierrez P et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33: E57-61.
184. Soto J, Arana BA, Toledo J et al. Miltefosine for NewWorld cutaneous leishmaniasis. Clin Infect Dis 2004; 38: 1266-72.
185. Vélez I, López L, Sánchez X et al. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83: 351-6.
186. Machado PR, Ampuero J, Guimarães LH et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010; 4: e912.
187. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011; 84: 255-60.
188. Rubiano LC, Miranda MC, Muvdi Arenas S et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 2012; 205: 684-92.
189. Mohebali M, Fotouhi A, Hooshmand B et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007; 103: 33-40.
190. Soto J, Toledo J, Valda L et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44: 350-6.
191. Soto J, Rea J, Valderrama M et al. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 2009; 81: 387-9.